The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure
Davies, M.-A.; Boulle, A.; Technau, K.; Eley, B.; Moultrie, H.; Rabie, H.; Garone, D.; Giddy, J.; Wood, R.; Egger, M.; Keiser, O.; Chimbetete, C.; Dickinson, D.; Eley, B.; Fritz, C.; Garone, D.; Giddy, J.; Hoffmann, C.; MacPhail, P.; Moultrie, H.; Ndirangu, J.; Pestilli, S.; Phiri, S.; Prozesky, H.; Chi, B.; Technau, K.; Vaz, P.; Wood, R.
Tropical Medicine and International Health Tm and Ih 17(11): 1386-1390
2012
ISSN/ISBN: 1365-3156 PMID: 22974345 DOI: 10.1111/j.1365-3156.2012.03073.xDocument Number: 578435
To determine the improvement in positive predictive value of immunological failure criteria for identifying virological failure in HIV-infected children on antiretroviral therapy (ART) when a single targeted viral load measurement is performed in children identified as having immunological failure. Analysis of data from children (<16 years at ART initiation) at South African ART sites at which CD4 count/per cent and HIV-RNA monitoring are performed 6-monthly. Immunological failure was defined according to both WHO 2010 and United States Department of Health and Human Services (DHHS) 2008 criteria. Confirmed virological failure was defined as HIV-RNA >5000 copies/ml on two consecutive occasions <365 days apart in a child on ART for ≥18 months. Among 2798 children on ART for ≥18 months [median (IQR) age 50 (21-84) months at ART initiation], the cumulative probability of confirmed virological failure by 42 months on ART was 6.3%. Using targeted viral load after meeting DHHS immunological failure criteria rather than DHHS immunological failure criteria alone increased positive predictive value from 28% to 82%. Targeted viral load improved the positive predictive value of WHO 2010 criteria for identifying confirmed virological failure from 49% to 82%. The addition of a single viral load measurement in children identified as failing immunologically will prevent most switches to second-line treatment in virologically suppressed children.